Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lead Pb 212-DOTAM-GRPR1

A radioconjugate consisting of a gastrin-releasing peptide receptor (GRPR)-targeting antagonist conjugated, through a bifunctional, macrocyclic chelating agent DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide; TCMC), to the alpha-emitting radioisotope lead Pb 212, with potential antineoplastic activity. Upon administration, lead Pb 212-DOTAM-GRPR1 targets and binds to GRPR-expressing tumor cells. This allows for the specific delivery of a cytotoxic dose of alpha radiation to GRPR-expressing tumor cells. GRPR, also called bombesin receptor 2 (BB2), is a G protein-coupled seven-transmembrane receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.
Synonym:212Pb-DOTAM-GRPR1
Pb212-DOTAM-GRPR1
Search NCI's Drug Dictionary